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Abstract
Background: ARETAEUS 1 study showed that a great majority of patients with type 2 dia-
betes mellitus (T2DM) of short duration did not meet all of the treatment goals. Since then the 
treatment goals in T2DM have been changed. The aim of the ARETAEUS 2-Grupa Study was 
to assess cardiovascular (CV) risk management and meeting treatment goals in the population 
of T2DM of more than 10-year duration.
Methods: ARETAEUS2-Grupa was a cross-sectional questionnaire-based study conducted 
in Poland in 2012. Randomly selected physicians recruited 1,740 patients with T2DM diag-
nosed more than 10 years before the study.
Results: Lipid treatment goals were met respectively: for total cholesterol in 34.5% of all patients, 
triglycerides in 53.8%, low density lipoprotein cholesterol (LDL-C) in 26.5% and high density 
lipoprotein cholesterol (HDL-C) in 38.2%. Most of patients with and without coronary artery 
disease were receiving aspirin (90.3% and 60%, respectively) and statins (84.4% and 67.7%, 
respectively). The current blood pressure (BP) goal (140/90 mm Hg) was met in 43.5% of pa-
tients and the previous goal (< 130/80 mm Hg) in 12.4%. The patients were mainly treated with  
≥ 3 antihypertensive drugs. All treatment goals (for HbA1c, BP and LDL-C) were reached only 
by 8.2% of patients, any two goals by 26.3% of patients, one goal by 39.8% of patients, none 
by 25.6% of patients.
Conclusions: The new less restrictive treatment goals are reached more frequently but still 
much is to be done in the field of clinical practice guidelines implementation and CV prevention 
in T2DM population. (Cardiol J 2015; 22, 2: 150–159)
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Introduction
The increasing prevalence of diabetes mel-
litus (DM) worldwide has led to a situation where 
approximately 360 million people had DM in 2011, 
of whom more than 95% were diagnosed with type 
2 DM (T2DM). Over 60% of people with T2DM 
develop cardiovascular disease (CVD), a more 
severe and costly complication than retinopathy. 
Thus, CVD risk should be given a higher priority 
in T2DM population. The problem of CVD risk in 
diabetes is noticed as very important in Europe and 
that is why European Society of Cardiology (ESC) 
in collaboration with the European Association for 
the Study of Diabetes developed clinical practice 
guidelines on diabetes, pre-diabetes, and CVD (last 
update in 2013) [1]. The management of cardio-
vascular (CV) risk in diabetes is also discussed in 
other ESC documents [2, 3].
In 2009, the ARETAEUS 1 study was con-
ducted and it showed that a great majority of pa-
tients with T2DM of short duration did not meet 
all of the treatment goals as recommended in the 
current practice guidelines [4, 5]. In 2011, Diabe-
tes Poland [6] updated its recommended goals in 
diabetes treatment, and in 2012, ESC [2] updated 
its guidelines on cardiovascular prevention. Ad-
herence to the updated guidelines has not been 
systematically assessed.
The main study aims were: 1) to assess the 
pharmacotherapy of T2DM patients and 2) to as-
sess the degree to which the diabetic control cri-
teria recommended in the current clinical practice 
guidelines developed by the Diabetes Poland [6, 7] 
(and ESC [2]) are met. This paper reports on CV 
risk factors prevalence and CV risk management 
in the population with T2DM lasting for more than 
10 years).
Methods
Detailed description of the ARETAEUS2-
-Grupa study design, protocol, questionnaire, in- 
clusion criteria for the study, recruitment proce-
dures of physicians and their patients and sample 
size calculations was published previously [8]. 
Briefly, ARETAEUS2-Grupa was a cross-sectional 
questionnaire-based study conducted in Poland 
(April–June 2012). The study included two groups 
of patients with T2DM: 1) diagnosed within the 
last 2 years and 2) diagnosed more than 10 years 
before the study commencement.
Treatment goal definitions from both Dia-
betes Poland [6, 7, 9] and ESC [1–3] guidelines 
were used. Diabetes Poland guidelines define treat-
ment goals in T2DM patients as: glycated hemo-
globin A1c (HbA1c) ≤ 7%, blood pressure (BP) 
< 140/90 mm Hg (this threshold was changed from 
130/80 mm Hg in 2011), total cholesterol < 4.5 ml/L, 
low density lipoprotein cholesterol (LDL-C) 
< 2.6 mmol/L (< 1.8 mmol/L if coronary artery 
disease [CAD] is present), high density lipoprotein 
cholesterol (HDL-C) > 1.0 mmol/L in men (and 
> 1.3 in women), triglycerides (TG) < 1.7 mmol/L. 
ESC treatment goals are different in the aspect of BP 
(<140/80 [2] or < 140/85 mm Hg [1, 3]) and LDL-C 
level < 2.6 mmol/L (< 1.8 mmol/L in very high 
risk patients defined as CAD or DM with one or 
more CV risk factors and/or target organ damage).
This paper concerns only patients with T2DM 
lasting > 10 years, participating in ARATAEUS2-
-Grupa Study, while the data on CV risk manage-
ment in patients with T2DM of short duration will 
be reported separately.
Statistical analysis
We compared proportions of patients achiev-
ing treatment goals in the subgroups with c2 test 
or Fischer’s exact test (when the expected values 
in any of the cells of a contingency table were 
below 5). For the comparison of the means the 
t-test was used (for normal distribution), and the 
Mann-Whitney U test and Kruskal-Wallis test (for 
non-normal distribution of the variable). The dis-
tribution was estimated on the basis of skewness 
coefficient and graphical picture. The t-test for 
equal or non-equal variances was used depending 
on the result of the Levene’s test. All statistical 
analyses were conducted using SPSS v 18.0.
Results
The patient and physician characteristics 
and the results related to diabetes control was 
described elsewhere [10]. Sixty per cent of all 
patients had HbA1c level above 7.0%.
Mean age of patients was 68 ± 10 years, 
54% were female, mean body mass index (BMI) 
was 30.6 ± 4.9 kg/m2, 48% had BMI > 30 kg/m2, 
68.5% were diagnosed with diabetes > 10–15 years 
before, 17.5% — ≥ 15–20 years before and 14% — 
> 20 years before.
CV risk factors were present in great majority 
of patients participating in the study: according to 
the physician report 97.4% patients had hyperten-
sion or received antihypertensive drugs (exclud-
ing beta-blockers after acute coronary syndrome 
[ACS]), 83.1% — lipid disorders, 18.1% — history 
of ACS, 48.5% — stable CAD, 8.9% — history of 
stroke, 10.7% — history of transient ischemic 
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attack, 53% were smokers and 31% ex-smokers. 
Mean systolic/diastolic arterial pressure in par-
ticipants with diagnosed hypertension was 139 ± 
± 15/81 ± 10 mm Hg and among those without 
such diagnosis 127 ± 11/76 ± 7 mm Hg. The coinci-
dence of various risk factors was very frequent 
(Table 1).
The mean lipid levels are presented in Table 2. 
Total cholesterol treatment goal (< 4.5 mmol/L) 
was met in 34.5% of all patients, TG treatment goal 
Table 1. Coincidence of cardiovascular risk factors in patients with type 2 diabetes mellitus lasting for 
more than 10 years.
Variable In overall population, % (n = 1,737)
Diabetes + hypertensiona 91.7 
Diabetes + hypertensiona + lipid disordersa 78.7 
Diabetes + hypertensiona + lipid disordersa + obesity 41.0 
Diabetes + hypertensiona + lipid disordersa + obesity + ex-smoking 13.2 
Diabetes + hypertensiona + lipid disordersa + obesity + smoking 5.7 
Diabetes + hypertensionb 93.4 
Diabetes + hypertensionb + lipid disordersa 79.5 
Diabetes + hypertensionb + lipid disordersa + obesity 41.3 
Diabetes + hypertensionb + lipid disordersa + obesity + ex-smoking 13.1 
Diabetes + hypertensionb + lipid disordersa + obesity + smoking 5.8 
Number in brackets — number of valid questionnaires; areported by physician; breported by physician or blood pressure ≥ 140/90 mm Hg
Table 2. Lipid level control and lipid lowering drugs in patients with type 2 diabetes mellitus lasting for 
more than 10 years.
Variable In overall  
population,  
% 
In patients using 
statins
In patients with  
the diagnosis  
of lipid disorders  
or taking hypo- 
lipidemic drugs 
In patients without 
the diagnosis  
of lipid disorders  
and not taking hypo-
lipidemic drugs 
Yes No
Total cholesterol N = 1,668 N = 1,405 N = 248
< 4.5 mmol/L 34.5 (576) 32.0 (450) 46.4 (115)
≥ 4.5 mmol/L 65.5 (1,092) 68.0 (955)* 53.6 (133)*
LDL-C N = 1,432 N = 1,111 N = 288 N = 1,208 N = 210
< 2.6 mmol/L or if CAD 
< 1.8 mmol/L
26.5 (379) 24.1 (268) 34.7 (100) 24.0 (290) 38.6 (81)
≥ 2.6 mmol/L or if CAD 
≥ 1.8 mmol/l
73.5 (1,053) 75.9 (843) 65.3 (188) 76.0 (918)* 61.4 (129)*
< 2.6 mmol/L or if  
very high CV risk  
< 1.8 mmol/L
15.2 (217) 15.3 (170) 14.2 (41) 14.6 (176) 18.1 (38)
≥ 2.6 mmol/L or if  
very high CV risk  
≥ 1.8 mmol/L
84.8 (1,215) 84.7 (941) 85.8 (247) 85.4 (1,032) 81.9 (172)
HDL-C N = 1,434 N = 1,218 N = 202)
> 1.0 mmol/L males,  
> 1.3 mmol/L females 
38.2 (548) 39.5 (481) 30.7 (62)
< 1.0 mmol/L males,  
< 1.3 mmol/L females 
61.8 (886) 60.5 (737)* 69.3 (140)*
Triglycerides N = 1,629) N = 1,383) N = 230)
< 1.7 mmol/L 53.8 (877) 49.8 (689) 76.5 (176)
≥ 1.7 mmol/L 46.2 (752) 50.2 (694)* 23.5 (54)*
Numbers in brackets — number of valid questionnaires; *significant difference between patients taking and not taking hypolipidemic drug 
(statin, fibrate); CV — cardiovascular; CAD — coronary artery disease; LDL-C — low density lipoprotein cholesterol; HDL-C — high density  
lipoprotein cholesterol
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(< 1.7 mmol/L) in 53.8%, LDL-C treatment goal 
(< 2.6 mmol/L or if CAD < 1.8 mmol/L — criterion 
defined in Diabetes Poland guidelines) in 26.5% 
(in 15.2% if < 1.8 mmol/L threshold was used for 
all patients with very high CV risk according to 
ESC guidelines [1, 3]) and HDL-C treatment goal 
(> 1.0 mmol/L in men and > 1.3 mmol/L in women) 
in 38.2%. There were significant differences in 
the numbers of patients achieving these targets 
between patients with the diagnosis of lipid disor-
ders (or taking hypolipidemic drugs) and without 
such a diagnosis (or not taking drugs). There were 
no significant differences between the subgroups 
using and not using statins (LDL-C treatment goal 
defined in Diabetes Poland guidelines was reached 
in 24.1% vs. 34.7% patients, respectively).
The use of acetylsalicylic acid (ASA), statins, 
fibrates, and beta-blockers in the studied patients is 
shown in Table 3. Most of patients with and without 
CAD were receiving ASA (90.3% and 60%, respec-
tively) and statins (84.4% and 67.7%, respectively). 
Ninety per cent of patients with a history of myo-
cardial infarction received beta-blocker (Table 3). 
The use of medications in different age subgroups 
is presented in Figure 1.
Percentages of patients falling into different 
categories of BP levels are shown in Table 4.
Regarding BP control, the treatment goal 
outlined in the last 3 editions of Diabetes Poland 
guidelines [6, 7, 9] (i.e. 140/90 mm Hg) was met 
in 43.5% of the overall population. The percentage 
was significantly higher in the subgroup of patients 
without the diagnosis of hypertension and not tak-
ing antihypertensive drugs as compared with pa-
tients with the diagnosis of hypertension or taking 
antihypertensive drugs (79.4% vs. 39.6%; Fig. 2A). 
The more restricted goal of BP below 130/80 mm Hg 
(which was used by Diabetes Poland in the 
guidelines until 2010 [11] when all study partici-
pants have already had T2DM) was achieved in 
12.4% of patients. The patients were mainly treat-
ed with ≥ 3 antihypertensive drugs (Fig. 2B). 
The majority received angiotensin converting en-
zyme inhibitor, beta-blocker, diuretic and calcium 
channel blocker; other drugs were used less fre-
quently (Table 5). Combination antihypertensive 
drugs were used in 14.9% of patients.
All treatment goals (HbA1c ≤ 7.0%, BP 
< 140/90 mm Hg and LDL-C < 2.6 mmol/L 
[< 1.8 mmol/L if CAD]) were reached only by 8.2% 
of patients, any two goals by 26.3% of patients 
(HbA1c and BP goals in 14.9%, HbA1c and LDL-C 
goals in 5.8%, BP and LDL-C goals in 5.6%), one 
goal by 39.8% of patients (HbA1c goal in 13.6%, BP 
goal in 18.2%, LDL-C goal in 8.0%), none by 25.6% 
of patients. The percentages of patients reaching 
three or two goals were smaller if LDL-C treatment 
goal was defined according to ESC guidelines (4.5% 
and 25.2%, respectively). Figure 3 represents the 
results of the analysis of the number (and type) of 
treatment goals met in the differently predefined 
subgroups of patients (with or without previous CV 
events; receiving different number of antihyperten-
sive drugs, receiving and not receiving statins and 
fibrates).
Discussion
ARETAEUS2-Grupa Study is the first Polish 
study addressing specifically patients with T2DM 
of more than 10-year duration. In this paper, the 
data on CV risk factors profile and management 
are presented.
Other Polish studies, OPTIMO [12] and 
DYNAMIC-2 [13], included respectively 24% and 
16% of patients with T2DM of more than 10-year 
duration. In The Polish Diabetes Registry for 
adults [14], mean diabetes duration was 9.7 years. 
Achieving all of the treatment goals (HbA1c, BP 
and lipid values) was very uncommon in those 
studies (regardless of the goal definitions), and 
the proportion of patients achieving one or two of 
these goals was also unsatisfactory.
We used goal definitions from both Diabetes 
Poland [6, 7, 9] and ESC [1–3] guidelines which 
differ in some aspects (see above). Since the 
time of diagnosis in all patients participating in 
ARETAEUS2-Grupa Study was described here, 
the thresholds of good CV risk control have been 
changed. Those changes in the treatment goals and 
the inconsistency between the guidelines of lead-
ing scientific societies make the implementation of 
these guidelines even more difficult, although this 
cannot be used as an excuse and the only explana-
tion for poor diabetes control. Additionally, some 
goals are not clearly defined and need ordering spe-
cial diagnostic tests, which are not so easily avail-
able in an outpatient clinic. An example could be 
the LDL-C level according to ESC guidelines [2], 
which was less frequently reached (in comparison 
to more clear goal of LDL-C control according to 
Diabetes Poland and previous ESC [15] guidelines 
— 15.2% vs. 26.5%).
The treatment goals are less restrictive now 
and this is the first survey in which rate of achiev-
ing these new goals was studied. Our study shows 
that they are reached in more patients but the 
level is still unsatisfactory. We cannot exclude the 
possibility that physicians do not pay enough atten-
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tion to prevention and do not find time to explain 
to patients its importance, and that patients with 
chronic disease are tired of all restrictions (life 
style modifications and multidrug regimens).
It is worth mentioning that 56% of all patients 
have BP > 140/90 mm Hg, although the frequency 
of using 3 or more antihypertensive agents was 
high (30.7 and 31.7%, respectively). A substantial 
change in the number of antihypertensives used 
in 1 patient is to be noticed during the last decade 
— in Dynamic II study [13], only 18.4% of patients 
received more than 2 of those agents. Therefore, 
it is possible that the problem of poor BP control 
is not connected with the number of drugs used 
but with adjustment of the dose or with patients’ 
compliance. However, the frequency of using 
combination drugs seems to be too low (14%); 
physicians should be encouraged to use them more 
often, because it may improve compliance [16].
The lipid control in our study participants 
is similar to that observed in the Polish Diabe- 
tes Registry for adults [14] — total cholesterol 
< 4.5 mmol/L was present in 34.5% vs. 32.6%, and 
TG < 1.7 mmol/L in 53.8% vs. 53.2% of patients. 
These data show some improvement as compared 
to the DEPAC survey [17] performed in Central 
and Eastern Europe (including Poland) at the time 
of accession to EU (2004) in which total choles-
terol < 4.5 mmol/L was present in 19.7% and TG 
< 1.7 mmol/L in 43.5% of participants. Although 
the difference could also be attributed to the fact 
that DEPAC included only secondary care patients, 
which focuses on patients with advanced diabetic 
complications and requiring treatment intensifica-
Table 3. Acetylsalicylic acid (ASA), statins and beta-blockers use in patients with type 2 diabetes  
mellitus lasting for more than 10 years.
Variable Percent of patients using  
the medicine (n)
Acetylsalicylic acid use 76.9 (1,294)
< 40 years (n = 11) 40 (2)
≥ 40 years (n = 1,672) 76.4 (772)
Without CAD (n = 806) 60 (284)
With CAD (n = 882) 90.3 (492)
Without CAD and < 40 years (n = 10) 30.0 (3)
Without CAD and ≥ 40 years (n = 789) 62.0 (489)
With CAD and < 40 years (n = 1) 100.0 (1)
With CAD and ≥ 40 years (n = 871) 90.9 (792)
Statin use (n = 1,699) 77.5 (1,317)
Without CAD (n = 805) 67.5 (543)*
With CAD (n = 882) 86.6 (764)*
LDL < 2.6 mmol/L or if CAD < 1.8 mmol/L (n = 368) 72.8 (268)^
LDL ≥ 2.6 mmol/L or if CAD ≥ 1.8 mmol/L (n = 1,031) 81.8 (843)^
LDL < 2.6 mmol/L or if CAD < 1.8 mmol/L AND
Without CAD (n = 257) 67.7 (174)
With CAD (n = 109) 84.4 (92)
LDL ≥ 2.6 mmol/L or if CAD ≥ 1.8 mmol/L AND
Without CAD (n = 402) 72.6 (292)
With CAD (n = 626) 87.5 (548)
LDL control according to ESC guidelines
LDL < 2.6 mmol/L or if CAD (or ≥ 1 risk factor) < 1.8 mmol/L (n = 211) 80.6 (170)
LDL ≥ 2.6 mmol/L or if CAD (or ≥ 1 risk factor) ≥ 1.8 mmol/L (n = 1,188) 72.6 (941)
Fibrate use (n = 1,608) 14.5 (233)
Beta-blockers use (n = 1,634) 65.2 (1,066)
Without a history of MI (n = 1,331) 59.4 (791)#
With a history of MI (n = 303) 90.8 (275)#
Numbers in brackets — number of valid questionnaires; *significant difference between patients with and without coronary heart disease 
(CAD); ^significant difference between patients with and without lipid control; #significant difference between patients with and without  
a history of myocardial infarction (MI); ESC — European Society of Cardiology; LDL — low density lipoprotein
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tion, our study included both primary and second-
ary care settings.
It is needed to mention that in the current 
ACC/AHA guidelines on the treatment of blood 
cholesterol to reduce atherosclerotic CV risk in 
adults, the LDL goals are not defined any more 
[18]. According to these guidelines, the patients 
at the age 40–75 with diabetes and LDL-C level 
> 70 mg/dL (1.8 mmol/L) moderate or high-inten-
sity statin therapy is recommended (dependent on 
LDL-C level < or > 189 mg/dL). Moderate and 
high doses of statins are defined as in clinical trials. 
However, this new approach was not accepted by 
European societies which still recommend that 
the ESC guidelines are followed [1, 2]. There are 
concerns that without obvious treatment goals the 
patient compliance can be worse.
The adherence to clinical practice guidelines 
is better when the recommendations are clear, 
simple and easy to follow (e.g. using specific drugs 
in specific clinical situations — ASA in CAD [90.3% 
of study participants with CAD received it] or 
Table 4. Categories of blood pressure levels in patients with type 2 diabetes mellitus lasting for more 
than 10 years.
Systolic blood pressure  
[mm Hg]
Diastolic blood pressure [mm Hg]








≥ 110  
(n = 10)
< 130 (n = 353) 60.6 (214) 38.2 (135) 1.1 (4) 0.0 0.0
130–140 (n = 464) 34.1 (158) 56.9 (264) 9.1 (42) 0.0 0.0
140–160 (n = 720) 20.0 (144) 42.5 (306) 31.1 (224) 6.4 (46) 0.0
160–180 (n = 160) 10.0 (16) 28.8 (46) 37.5 (60) 18.8 (30) 5.0 (8)
≥ 180 (n = 26) 7.7 (2) 19.2 (5) 19.2 (5) 46.2 (12) 7.7 (2)
Figure 1. The prevalence of coronary artery disease, lipid disorders and hypertension and the use of medications in 
different age subgroups; ASA — acetylsalicylic acid; CAD — coronary artery disease.
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Figure 2. A. Blood pressure (BP) control and previously diagnosed hypertension in patients with type 2 diabetes mel-
litus lasting > 10 years; B. Number of antihypertensive drugs used in the whole population and the subgroups with 
elevated and with normal BP.
Table 5. The use of all classes of antihypertensive drugs.
Drug class (number of valid questionnaires) All  
participants
Participants with 
BP < 140/90 mm Hg BP ≥ 140/90 mm Hg
ACEI (n = 1,660) 71.9 (1,193) 61.2 (353)* 76.2 (559)*
ARB (n = 1,619) 22.3 (361) 20.6 (117) 23.4 (169)
Beta-blocker (n = 1,670) 65.4 (1,092)
Beta-blocker in patients without MI (n = 1,634) 48.4 (791) 56.9 (330) 61.3 (451)
Calcium channel blocker (n = 1,631) 41.2 (672) 30.7 (174)* 48.3 (351)*
Diuretic (n = 1,671) 64.8 (1,083) 52.9 (307)* 66.5 (497)*
Alpha-blocker (n = 1,595) 9.7 (155) 8.6 (49) 9.0 (63)
Combination drug (n = 1,620) 14.9 (242) 11.7 (67)* 17.1 (123)*
Numbers in brackets — number of valid questionnaires; *significant difference between patients with and without blood pressure (BP) control; 
ACEI — angiotensin converting enzyme inhibitor; ARB — angiotensin receptor blocker
beta-blocker in patients with previous myocardial 
infarction [90.8% of this population received this 
drug]). However, it should be mentioned that 
60% of patients without CAD received ASA. It is 
not clear if ASA was used as primary prevention 
in these cases or if the treated patients suffered 
from other CVD. There is much inconsistency 
about ASA use in primary prevention. Diabetes 
Poland guidelines [6, 7, 9] recommended ASA if 
10-year CAD risk is > 5%. ESC guidelines on 
prevention [2] do not recommend the use ASA 
in T2DM patients without clinical evidence of 
atherosclerotic disease (class of recommenda-
tion III, level of evidence A). The most recent 
ESC guidelines recommend considering ASA in 
high-risk patients with DM on an individual basis 
(class of recommendation IIb, level of evidence C). 
This inconsistency of guidelines may contribute to 
possible overuse of ASA for primary prevention 
in T2DM in our study.
Finally, it is necessary to mention that manage-
ment of CV risk factors in diabetic patients is chal-
lenging and is regarded as unsatisfactory not only 
in Poland but also in other countries from EU and 
outside Europe [19–24]. Of note, it was observed 
by Polish researchers [25] that control of CV risk 
factors was better in CAD patients than in diabetic 
patients, although still unsatisfactory in most of 
them; it shows that DM is still not perceived as 
dangerous and life-threatening as CAD.
A B
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Limitation of the study
Obviously, we realize that our study is not 
free from limitations. The cross-sectional design 
of the study does not provide us with long-term 
data. As a result of the different T2DM durations 
in the participants, the median or mean values of 
the parameters may not be informative. To get the 
representative sample of the population with T2DM 
of more than 10-year duration we randomly selected 
physicians participating in our study separately from 
diabetologists and non-diabetologists (stratified by 
size of the place of residence) and we introduced 
patient selection on a pseudo-random basis.
However, the data collected from the physi-
cians were not verified and this may be associated 
with bias toward better results.
Another limitation is the fact that hypertension 
and lipid disorders were recognized on the basis 
of physician’s opinion as well as the use of antihy-
pertensive or hypolipidemic agents, respectively. 
This fact and the long duration of diabetes may be 
the reasons why the hypertension was recognized 
more often in our population than in other studied 
groups with diabetes.
Conclusions
The results of the ARETAEUS2-Grupa Study 
provide valuable information about CV risk factors 
prevalence and CV risk management in T2DM of 
more than 10-year duration. This information is use-
ful for all people engaged directly or indirectly in the 
care of T2DM patients: doctors, nurses, university 
tutors and experts developing and implementing 
practice guidelines in Poland and other countries. It 
is obvious that new less restrictive treatment goals 
would be reached more frequently but significant 
improvement may still be achieved in the field of 
clinical practice guidelines implementation and CV 
prevention in T2DM population. Another compo-
nent of successful treatment in chronic diseases 
is patients’ awareness of the treatment goals, and 
more effort should be put into increasing compliance 
of the patients. It is also essential to elaborate the 
Figure 3. Number of treatment goals met in the different subgroups of ARETAEUS2-Grupa Study; CV — cardiovas-
cular; HT — hypertensive.
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strategies to improve medical care in T2DM and 
surveillance of preventive-care practices and treat-
ment goals among affected individuals for planning 
further initiatives that would reduce the burden of 
CV complications in T2DM patients.
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